A 59-year-old with HFrEF (EF 25%) on ARNI, β-blocker, MRA, and SGLT2 inhibitor remains symptomatic (NYHA III), Black race. What additional therapy red...

Question

A 59-year-old with HFrEF (EF 25%) on ARNI, β-blocker, MRA, and SGLT2 inhibitor remains symptomatic (NYHA III), Black race. What additional therapy reduces mortality?

Accepted Answer

Hydralazine-isosorbide dinitrate

Answer

Diltiazem

Answer

Ivabradine first-line

Answer

Digoxin to reduce mortality

Answer

Loop diuretic monotherapy

us-abim MCQ (SBA): Heart Failure (HFrEF)

A 59-year-old with HFrEF (EF 25%) on ARNI, β-blocker, MRA, and SGLT2 inhibitor remains symptomatic (NYHA III), Black race. What additional therapy reduces mortality?